Sermorelin Acetate 10 mg

Compound profile

Sermorelin: compound profile, literature landscape and handling notes

Where Sermorelin came from

Growth hormone-releasing hormone was isolated in the early 1980s, later than most of the hypothalamic releasing factors, and by an unusual route. The hypothalamic source material was too scarce to work with, so the sequence was recovered instead from pancreatic islet cell tumors that were producing the hormone ectopically in large quantity. Two groups working on that tumor material published the sequence within a short window, and the native peptide turned out to exist in more than one C-terminal form, a 44-residue amidated species and a shorter 40-residue acid species, generated from the same precursor by differential processing.

The structure-activity work followed immediately and was unusually systematic, because the peptide was long enough that everyone involved wanted to know how much of it was actually necessary. The answer, established by making and testing a ladder of truncations, was that activity survived deletion from the C-terminus much further than anyone expected, and collapsed abruptly with deletion from the N-terminus. Removing the first residue destroyed activity. Removing fifteen residues from the far end did not. The 1-29 amide sat at the point where the curve was still flat, and it became the standard short form. It was given the name sermorelin, and the acetate salt was the form that entered development.

That development history is the second thing worth knowing about this compound. Sermorelin acetate was commercialized decades ago, carried a brand name for a period, and was later withdrawn from the market in a decision reported at the time as a commercial one rather than one driven by any new finding about the molecule. The patents have long since lapsed. The practical consequence for a research buyer is that sermorelin is now made by many suppliers with no originator program behind it, and that the body of literature attached to its name accumulated mostly before modern analytical standards, and has not been systematically refreshed since.

Reading the structure of Sermorelin

The sequence, formula and mass for this listing are printed in the specification table further down this page. What matters here is what the two defining structural decisions in that string are for, because sermorelin is essentially a molecule defined by two edits to a natural sequence: it is cut short, and its new end is capped.

The truncation is the interesting one. Peptide hormones in this family bind their receptors in two distinct pieces, and the pieces do different jobs. The C-terminal portion of the ligand docks against the large extracellular domain of the receptor and supplies most of the binding energy; the N-terminal portion then inserts into the transmembrane bundle and is what actually triggers the conformational change that turns the receptor on. This two-domain model explains the truncation ladder cleanly. Cut from the C-terminus and you remove affinity and stability, so the peptide needs more of itself present to do the same work, but each molecule that does bind still activates fully. Cut from the N-terminus, even by one residue, and you remove the activation signal itself, which is why the des-tyrosine form is not a weak agonist but effectively an inactive fragment. Sermorelin is the truncation taken to the point where enough of the C-terminal helix remains to hold the receptor, and no further.

The amide cap is the second edit. In the native 44-residue species the C-terminal amide is installed enzymatically from a glycine-extended precursor; in a synthetic 1-29 fragment it is installed by building the chain on an amide-forming resin. It does three things at once. It removes the negative charge that a free C-terminal carboxylate would introduce at the new end, which the native sequence never had there. It closes off the substrate that carboxypeptidases recognize. And it stabilizes the C-terminal end of the amphipathic helix that this region of the sequence forms, which is the structural element the receptor extracellular domain reads. The free-acid version of the same fragment is a real and separately characterized compound and is not equivalent to the amide. If documentation for a lot does not speak to the amide explicitly, that is a gap worth closing before the material is used in anything comparative.

The target and the pathway in more detail

The GHRH receptor is a class B secretin-family G-protein-coupled receptor, the same broad architecture as the receptors for the incretin peptides elsewhere in this catalog, and its canonical coupling is to Gs. Agonist occupancy raises intracellular cyclic AMP, activates protein kinase A, and drives phosphorylation of CREB, which in turn acts on transcription of the growth hormone gene and on the transcription factor that specifies the somatotroph lineage. The receptor is expressed at high density on anterior pituitary somatotrophs and much more sparsely elsewhere, and a truncated splice variant of the receptor has been described in various tumor tissues and is the subject of a separate literature that should not be conflated with the pituitary one.

Two features of the pathway are worth holding onto because they shape how experiments with sermorelin read out. The first is that GHRH-receptor signaling is both an acute secretory signal and a slower trophic and transcriptional one. A short exposure in a cell system reports the first. A longer exposure reports something that includes the second. Papers that appear to disagree about the magnitude of an effect are often reporting different arms of this at different time points. Sustained occupancy also engages the usual class B regulatory machinery, receptor phosphorylation, arrestin recruitment and internalization, so a continuous exposure and a pulsed one with the same total exposure are not equivalent stimuli and should not be compared as though they were.

The second is that in an intact system the GHRH receptor never operates alone. Somatotroph output is set by the balance between GHRH-receptor input, tonic inhibitory input through somatostatin receptors, and a third input through the growth hormone secretagogue receptor GHS-R1a, which responds to ghrelin and to synthetic secretagogues and couples to Gq and phospholipase C rather than to Gs. Those three signals converge on the same cell through different second messengers, and the interaction between them is not additive. The published synergy between GHRH-receptor and GHS-R1a agonism, which is real and reproducible in isolated pituitary preparations, is a consequence of two different second-messenger systems converging, not of two ligands acting at one site. This is the mechanistic reason a GHRH fragment and a ghrelin-receptor agonist are not substitutes for one another, and it is also the reason they are so often studied together.

What the published literature on Sermorelin actually measures

The sermorelin literature is best understood as three strata laid down at different times, and a citation is only useful once you know which stratum it came from.

The oldest and, for bench purposes, the most valuable stratum is the structure-activity chemistry from the 1980s. This is the work that built and tested the truncation series, established that the 1-29 amide retained full intrinsic activity, mapped which N-terminal residues were indispensable, and characterized what happens when individual positions are substituted. It was done with pituitary cell preparations and growth hormone release as the readout, and it is the reason sermorelin exists at all. It is also the part of the record that is most reliably reproducible, because the assays were simple and the questions were narrow.

The middle stratum is metabolic and pharmacokinetic. This is where the identification of dipeptidyl peptidase-4 as the dominant clearance route for GHRH peptides sits, along with the characterization of the resulting 3-29 and 3-44 fragments and their much reduced activity. This work is the direct ancestor of every stabilized GHRH analog that came afterward, and it is the reason a modern GHRH-derived compound either has an N-terminal acyl group or a substituted second residue.

The third stratum is clinical and clinical-adjacent. Sermorelin was studied in pituitary function work and in pediatric endocrinology, and it accumulated a body of writing in clinical practice journals, review articles and, more recently, in material produced for compounding and wellness markets. This stratum is by far the largest by volume and by far the least useful at a bench. It does not characterize the molecule. It reports outcomes in people under conditions that no in vitro protocol can reference.

What is conspicuously thin is the fourth stratum you would expect to find and mostly do not: modern independent work using sermorelin as a tool compound with contemporary methods, recombinant receptor systems, quantitative cyclic AMP readouts and mass-spectrometric confirmation of the material used. Some exists. There is much less of it than there is for compounds a fraction of its age.

Where the Sermorelin literature is thin or frequently misread

The central problem with the sermorelin record is one of proportion. This is a very old compound that is discussed constantly, and the ratio of discussion to primary pharmacology is worse here than for almost anything else in this catalog. A large fraction of what circulates under the compound's name is clinical-practice commentary, review-of-reviews material, or content produced to market a preparation. None of that is peer-reviewed pharmacology, and a claim that appears in fifty such sources is still a claim with one origin.

The specific failure mode this creates is the untraceable assertion. Statements about relative potency against other GHRH analogs, about receptor selectivity, about comparative stability, and about the behavior of the compound in solution are repeated widely without any citation that terminates in a primary measurement. When you trace them, a surprising number end at a manufacturer document, a conference abstract, or a review that cites another review. Before building an experiment on any quantitative claim about sermorelin, trace it to a paper with a methods section.

The second gap is that the patents lapsed long ago and no originator program maintains the compound. There is no single well-characterized reference material that the field converges on, and no continuing body of work that recharacterizes it as methods improve. Material sold under this name therefore varies more between suppliers than material with an active originator behind it, and the analytical documentation supplied with a specific lot, rather than the name on the label, is what establishes what you are holding.

The third is over-extrapolation from acute preparations. Much of the classical work used isolated pituitary cells and a short stimulation window. That design is excellent for the question it was built for and says nothing about receptor desensitization, downstream feedback, or anything that develops over a longer timescale. Conclusions about sustained signaling drawn from acute release data are not supported by the data they cite.

How Sermorelin behaves in solution

The single most important handling fact about sermorelin is that it has no built-in protection against the enzyme that degrades it. Dipeptidyl peptidase-4 cleaves after the second residue of the sequence, releasing the N-terminal tyrosine-alanine dipeptide and leaving a 3-29 fragment that has lost the activation signal described above. Sermorelin carries the native residue at position two, entirely unmodified. Every later GHRH-derived compound in this catalog exists because of that cleavage: some block it with an acyl group on the N-terminal amine, some with a D-amino acid or other non-proteinogenic substitution at position two. Sermorelin blocks it with nothing. In any matrix containing serum, plasma, whole blood, tissue homogenate or cultured cells with membrane peptidase activity, this reaction is fast and it is the dominant route of loss. If an experiment needs the intact peptide to persist, the matrix has to be characterized for peptidase activity or an inhibitor has to be included and recorded, and either way the loss should be measured rather than assumed to be small.

Outside a biological matrix the behavior is that of an ordinary hydrophilic peptide of this length, with two named liabilities. The methionine near the C-terminal end oxidizes to the sulfoxide on exposure to air, peroxide contamination in buffers, or light, and oxidation is cumulative and irreversible in practice. The asparagine in the N-terminal third deamidates, faster at alkaline pH and at elevated temperature, and the aspartate-alanine pair near the N-terminus is a recognized site for cyclic imide formation under acidic conditions. Neither reaction produces anything you can see.

The visible failure signs are the usual ones and they are late signs, not early ones. Cloudiness, a wisp or thread in an otherwise clear solution, a film on the vial wall, or a lyophilized cake that has slumped, browned or gone tacky all indicate that something has already happened. A clear solution proves nothing. Adsorption to container surfaces is real at low concentration, favor low-binding labware and few transfer steps, and freeze-thaw cycling should be treated as a cost rather than a convenience. Storage conditions in the specification table above are the product record for this material and should be confirmed against the documentation supplied with the lot.

Analytical notes specific to Sermorelin

Two features of sermorelin make it more awkward to characterize than its modest size suggests, and both are consequences of the design decisions described earlier.

The first is the amide. The C-terminal amide and the corresponding free acid differ by about one mass unit. So does the difference between an intact asparagine and its deamidated product. On a low-resolution instrument, and on a certificate that reports a single average observed mass against a calculated one, those species are not reliably distinguished from each other or from the intended molecule, and a mass that looks correct to within a unit or two is not evidence that the amide is present and intact. Confirming the C-terminal amide specifically calls for either high enough resolving power to separate the isotope pattern properly or fragmentation that reads the C-terminal ion series. Methionine oxidation, by contrast, is a clean sixteen-unit shift and is easy to see if anyone looks for it.

The second is the ultraviolet chromophore, or the lack of one. The sequence has no tryptophan. Detection at 280 nanometers rests on two tyrosines only, which makes the response weak and the sensitivity poor at low concentration. Purity by reversed-phase chromatography for this compound is therefore normally read at low ultraviolet wavelength off the amide bond, where every peptide-like impurity also responds. That is the right choice, but it means the trace is crowded and that the closely eluting related substances, the des-amido form, the oxidized form, the deletion sequences that survive an imperfect synthesis, sit near the main peak rather than away from it. Area percent at a single wavelength cannot separate them with confidence, which is why identity by mass spectrometry sits alongside purity by chromatography and not in place of it.

Finally, the acetate. Peptide content, meaning how much of the gross weight in a vial is peptide rather than acetate counter-ion and residual water, is a third measurement again, distinct from both purity and identity, and it is the one most often missing. For a basic peptide such as this one, carrying several arginine and lysine side chains, the counter-ion burden is not a rounding error. Comparing two suppliers on labeled milligrams alone compares gross weights, not peptide.

Compounds researchers confuse with Sermorelin

Questions specific to Sermorelin